Hero image
Our commitment

Pulmonary hypertension

Every single life motivates us, day after day, to give our best.

Pulmonary hypertension is a rare chronic disease that can be life-threatening if left untreated. At MSD, we are committed to people who are affected by this disease.

Pulmonary hypertension (PH) is a chronic disease characterised by increased blood pressure in the pulmonary circulation. It may lead to a significant impairment of physical capacity and can be life-threatening if left untreated. There are various treatment options that aim to alleviate symptoms, stop progression of the disease and maintain the highest possible quality of life.

Find out more

Our commitment in the area of pulmonary hypertension

For over
5

years committed to improving the lives of patients in Switzerland

In the year
2013

introduction of the first soluble guanylate cyclase (sGC) stimulator for PH in Switzerland

Active since
2016

in longstanding partnerships and projects

Our partnerships and projects

Collaboration with the Schweizerische Gesellschaft für Pulmonale Hypertonie [Swiss Society for Pulmonary Hypertension] (SGPH)

The SGPH is panel of experts that for more than 20 years has bundled all findings about pulmonary hypertension into one efficient network. We have supported the SGPH for years in different projects and initiatives.

Cooperation with patient organisations

We have been involved for years in collaborative partnerships with patient organisations and the Swiss PH Society for people with pulmonary hypertension.

Continuing education events and conferences

MSD regularly takes part in the conference of the Schweizerische Gesellschaft für Pneumologie [Swiss Society for Pulmonology] (SGP) and supports continuing education events for physicians in order to help clarify pulmonary hypertension and its treatment.

Clinical Research

For almost 130 years, we have conducted research worldwide to contribute to better health for our society with our medications and vaccines, for today and future generations. In Switzerland, MSD is currently conducting 34 clinical studies in different areas of therapy (as of 11/2021).

Find out more

Information and education

Especially in November, during Pulmonary Hypertension Awareness Month, and on 5 May, World Pulmonary Hypertension Day, we raise awareness of the disease and the importance of early detection among the general public.

article quote image

"The sooner pulmonary hypertension is diagnosed and treated, the sooner a patient can benefit from an improvement in the quality of his or her life. With our commitment, we wish to contribute to the clarification and early detection of the disease".

Claudia Kimmich

Senior Customer Engagement Specialist Pulmonary Hypertension, MSD Schweiz

CH-NON-01417, 10/2021